利好来了！中国疫苗行业协会重磅发声

Core Viewpoint - The China Vaccine Industry Association has issued an initiative to combat "involution-style" competition and promote high-quality development in the vaccine and related biological products industry, emphasizing the prohibition of bidding below cost [2][5]. Group 1: Initiative Details - The initiative mandates all members of the China Vaccine Industry Association to adhere to the Vaccine Administration Law and the Price Law of the People's Republic of China, using production costs and market supply-demand as the basis for pricing [5]. - Members are required to resist disorderly low-price competition and are strictly prohibited from participating in bidding below cost, ensuring the quality standards of products and services [5][6]. - The initiative encourages members to focus on innovation-driven development, advancing key core technology breakthroughs and the research and application of innovative products [5]. Group 2: Industry Context - The domestic vaccine industry has faced significant pressure in recent years due to economic downturns, declining birth rates, and reduced vaccination willingness, leading to frequent price wars among vaccine companies [6]. - In the HPV vaccine sector, a price war initiated by Watson Bio in 2022 has resulted in the price of the bivalent HPV vaccine dropping below 100 yuan for the first time in 2024, with the lowest price reaching 27.5 yuan per dose [6]. - In the influenza vaccine market, China National Pharmaceutical Group initiated a price reduction for its quadrivalent influenza split vaccine in 2024, forcing other manufacturers like Hualan Biologicals to engage in price competition [6][7].